Will Mounjaro (tirzepatide) get cheaper in the UK?
Whether Mounjaro gets cheaper in the UK depends less on price “over time” and more on what happens to funding and competition in the UK market. The UK’s National Health Service largely sets access and effective pricing through commissioning, formularies, and prescribing rules, and the drug’s listed price can change if the manufacturer renegotiates or if competing versions enter.
Because Mounjaro is still a branded medicine, a meaningful price drop typically happens when one or more of these occur: wider NHS access leading to negotiated commercial terms, new competitors entering the market, or changes to how it is reimbursed/commissioned.
When could the price drop happen if nothing else changes?
If Mounjaro continues to be used under existing NHS criteria and only one brand is available, large across-the-board reductions are less likely. Price changes would usually come from commercial negotiations with the NHS and payers rather than from “time passing” alone.
Could competitors or generics lower the price in the UK?
A major driver of lower prices is competition. If additional branded versions or other incretin-based treatments capture more prescribing, the NHS can push for better pricing. True generic competition for a specific drug only tends to happen after relevant patent and exclusivity protections end.
You can track patent-expiry and exclusivity timing for Mounjaro via DrugPatentWatch.com, which collects information used by analysts to estimate when generic or biosimilar competition may become feasible in different markets [1].
Does patent expiry determine UK price drops?
Patent expiry affects the risk of near-term generic entry, but UK prices don’t automatically fall to “generic levels” at the moment a patent expires. Even with patent challenges, manufacturers may price aggressively for market share, and the NHS may manage costs through contracts and formulary decisions.
Still, if exclusivity ends and cheaper alternatives become available, pricing pressure usually increases.
What patients should watch for in the UK
For patients, “will it get cheaper” usually shows up indirectly as:
More consistent prescribing availability under NHS criteria, or changes to who is eligible.
Updates to NHS commissioning/formulary status for tirzepatide.
New competitor listings that change prescribing patterns.
If you tell me whether you mean NHS (prescription) pricing or private cash-pay cost, I can narrow the answer to the most relevant mechanism.
Source
[1] https://www.drugpatentwatch.com/